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ABSTRACT 
Introduction: Previous studies on laboratory animals have evaluated the effects of CGA 
(chlorogenic acids) rather than GCBE (green coffee bean extract), and few studies have been 
conducted on human models. Thus, the purpose of the present study was to assess the effect of 
GCBE consumption on serum oxidized LDL-cholesterol (OX-LDL) and total antioxidant capacity 
(TAC) on patients with dyslipidemia. 
Method: In this randomized, placebo-controlled, clinical trial, 70 male participants (age range 30 
to 55 years) were assigned from the outpatient clinic of Arvand Petrochemical Company in Mah-
shahr, Ahwaz, Iran to use 800 mg/day GCBE supplements or placebo for 8 weeks. Serum TAC 
and OX-LDL were determined by enzyme-linked immunosorbent assay. 
Results: Compared with the placebo, GCBE intake led to a significant reduction in OX-LDL (-
31.18 ng/ml) (P-value= ˂0.001) and a significant increase in TAC (71.73 μmol/l) concentration 
(P-value= 0.029). In the intervention group, GCBE supplementation resulted in a significant 
reduction in Oxidized LDL of -16.08±33.30 (ng/ml) (P-value= 0.006), compared to baseline. 
Conclusions: The current trial showed that the intake of 800 mg per day of GCBE may have 
favorable effects on TAC, and OX-LDL in patients with dyslipidemia. However, further studies 
are required to confirm the veracity of these results. 
Keywords: Green coffee Bean extract, total antioxidant capacity, randomized control trial, 
Oxidized LDL 
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Introduction 
Non-communicable diseases (NCD), including cardiovascular diseases (CVD), cancer and 
diabetes are among the leading causes of disability and mortality, globally [1]. For example, CVD 
account for 80% of all NCD deaths in the world [2]. Dyslipidemia, hypertension, hyperglycemia, 
abdominal obesity, diet factors, lack of physical activity and smoking are considered to be the 
main risk factors for CVD [3-5]. Moreover, oxidative stress and inflammation are reportedly linked 
with mortality in cardiovascular diseases; in addition, the activity of antioxidant enzymes and non-
enzyme antioxidants with total antioxidant capacity as a predictor of coronary artery disease has 
been reported [6]. Dyslipidemia is a disease characterized by various disorders in the lipid profile 
that increase the serum concentrations of total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C) and triglyceride (TG), and decrease the serum high-density lipoprotein 
cholesterol (HDL-C) levels [7]. The role of oxidative stress in the development and progression of 
CVD is well-recognized, due to its involvement in the pathogenesis of dyslipidemia and 
atherosclerosis, and attributed to oxidized LDL-C, which is derived from LDL oxidation by 
various processes [8]. Empirical evidence has demonstrated that dyslipidemia is a preliminary and 
important modifiable risk factor for CVD, and successfully managing serum lipids concentrations 
can, conceivably, reduce the mortality rate of CVD [9, 10]. Moreover, it has been shown that 
atherosclerosis may be improved by reducing serum LDL oxidized concentrations, even in the 
presence of high concentration of TG and LDL [11]. Lifestyle interventions and drug therapy are 
two major approaches to the treatment of dyslipidemia and, according to the latest American Heart 
Association guidelines, approaches to prevent CVD may also include healthy diet pattern, 
controlling weight, and maintaining lipid profile and blood pressure in a normal range [12]. Several 
epidemiologic studies have shown that the intake of food rich in antioxidants, such as vitamins (A, 
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C, and E) and polyphenols can reduce deaths attributed to CVD [13, 14]. Therefore, antioxidant 
intake and the effect of the nutritional supplementation on CVD is receiving growing, 
contemporary interest. Polyphenols are a major group of antioxidants that are extensively 
dispersed in foods such as coffee, apples, tomatoes, chocolate and tea. Green coffee bean extract 
(GCBE) is rich in polyphenols that promote defensive factors against chronic diseases initiated by 
oxidative stress [15]. Phenolic compounds with antioxidant characteristics are found abundantly 
within GCBE as a family of esters formed by several hydroxycinnamic acids (caffeic, ferulic and 
coumaric acids) and quinic acid, collectively known as chlorogenic acids (CGA) [16]. The anti-
inflammatory and antioxidant features, along with anti-carcinogenic characteristics of CGA and 
GCBE may play an important role in prevention and treatment of various chronic diseases, such 
as obesity, type 2 diabetes, cardiovascular dysfunction and cancers. Various animal studies have 
indicated the ameliorating effects of GCBE supplementation on chronic diseases such as 
hyperlipidemia, hypertension, diabetes and obesity [17-19]. Moreover, it has also been 
demonstrated, in laboratory animals, that CGA are among of the most effective constituents of 
green coffee and can decrease Fasting Blood Sugar (FBS) [20], Hemoglobin-A1c (HbA1c) [20], 
TG, TC, LDL-C and OX-LDL [21, 22]. Some human studies have demonstrated the beneficial 
effects of GCBE and CGA supplementation on blood pressure [23, 24], lipid profile [25], body 
weight, body mass, fat mass indices [24, 25] and serum levels of FBS [24]. In addition, CGA have 
been asserted capable of increasing total antioxidant capacity (TAC) [26, 27], and decreasing some 
inflammatory biomarkers [27, 28]. Previous studies have evaluated the effects of CGA, rather than 
GCBE, in laboratory animals, and few studies have been conducted on humans. Furthermore, no 
interventional study has been conducted investigating how GCBE supplementation effects patients 
with dyslipidemia.  It is essential to explore potential efficacious treatments for dyslipidemia, 
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particularly if it can help he prevention of cardiovascular diseases. The purpose of the present 
study was to assess the effect of GCBE consumption on serum OX-LDL and TAC in patients with 
dyslipidemia.  
 Material and Methods 
Study Design 
The present study was designed as a randomized, double-blind, parallel, placebo-controlled 
clinical trial. This study was conducted according to the principals of the Declaration of Helsinki 
and the study protocol was approved by the ethics committee of Ahvaz Jundishapur University of 
Medical Sciences (No. IR.AJUMS.REC.1396.899). This trial was also registered in the Iranian 
Registry of Clinical Trials (registration number: IRCT20180128038540N1). Written informed 
consent to participate in this study was provided by all of the volunteers and participants were 
informed about the aims and procedures prior to study commencement. A questionnaire regarding 
history of chronic disease, smoking status, demographic data, drug and dietary supplement history, 
prescribed medication and food habits was completed during participant interviews at the 
beginning of the study.  
Study Participants 
In this clinical trial, a total of 78 adult men with new diagnosis of dyslipidemia were included in 
the randomization process (Figure 1). Patients with dyslipidemia were recruited from the 
outpatient clinic of Arvand Petrochemical Company in Mah-shahr, Ahwaz, Iran. All participants 
were male because most employees were male, and therefore out of the operational control of the 
study. Disease status was confirmed according to the findings of an initial blood lipid profile test. 
Sample size and power 
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We used the standard formula suggested for parallel clinical trials n = [(Zα/2 + Z1-β)
2 × (2 S2)]/ (μ1 
- μ2)2  and S2=()n1-1)S12+(n2-1)S22)/n1+n2 -2 for estimating sample size by considering the type 1 
error (α) of 0.05 and type 2 error (β) of 0.20 (power = 80%)[29]. Based on a previous study on 
oxidized low density lipoprotein, standard deviations were obtained (SD1=35.4 for control and 
SD2=25.71 for intervention group)[30]. With a forecast of 10-15 units of change in mean oxidized 
low density lipoprotein based on the previous study[31], the final sample size was determined to 
be 68 participants (34 per group). 
Inclusion and Exclusion Criteria  
Eligible patients were employees at Arvand Petrochemical Company,  ere  ana diagnosed with 
dyslipidemia if they satisfied 2 or more of these disorders: total cholesterol >200mg/dl, 
triglyceride>150mg/dl, LDL-C>130mg/dl, HDL-C <40 mg/dl [7], did not consume any chemical 
or herbal medicine that might affect the blood glucose level and lipid profile and not having cancer, 
cardiovascular diseases, endocrine, liver or kidney dysfunction. Patients were excluded for the 
following reasons: coffee intolerance, coffee addiction, recent weight gain or weight loss, 
vegetarian diet and consumption of any antioxidant or dietary supplement in the 6 months 
preceding the beginning of the trial. 
Intervention 
A total of 78 dyslipidemic adult men were randomized, by random number tables, into an 
intervention or a control group. Participants in the intervention and control groups received either 
an oral dose of GCBE or placebo capsules (manufactured by Sabzdaru Co, Isfahan, Iran) twice per 
day, half an hour before lunch and dinner, respectively. Each GCBE capsule contained 400 mg of 
decaffeinated GCBE with 50% chlorogenic acid and each placebo capsule contained 400 mg of 
starch. Both the GCBE and the placebo capsules were identical in shape, color and size. The 
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duration of the trial was 8 weeks. The dosage of GCBE and intervention period have been verified 
according to previous studies[32, 33]. We contacted subjects weekly to ensure they followed the 
supplementation procedure. 
Dietary intake Assessment 
All participants were advised not to change their dietary intake and physical activity during the 
study. Dietary intake, including total energy, fiber, fat, carbohydrate, and protein was evaluated 
by using 3-day validated food recall questionnaire (2 weekdays and 1 weekend day) for all 
participants at the beginning and the end of study. Energy and dietary nutrient content were 
calculated from the Iranian National Food Composition Tables [34], using modified nutritionist 
IV software (version 3.5.2, First DataBank; Hearst Corp, Sun Bruno, CA, USA). 
 Physical activity and Anthropometric Assessments 
We used the International Physical Activity Questionnaire (IPAQ) [35] for assessing physical 
activity level at baseline and at the end of intervention. The participants were clustered into low, 
moderate, and high physical activity level. Weight, waist circumference, and fat mass of the 
participants were assessed, and BMI was computed at the beginning and at the end of trial. Height 
was determined, without shoes, using standard procedures and a tape measure with precision of 
0.5 cm at baseline. Weight was recorded, with minimal clothing and barefoot, using a digital scale 
(SECA, Hamburg, Germany) to the nearest 0.1 kg. BMI was calculated as weight (kg) divided by 
height in square meters. Waist circumference (WC) was measured using a tape measure with 
precision of 0.5cm at the midpoint between the last rib and iliac crest, without any pressure applied 
to the body surface. Fat mass was assessed via the bioelectrical impedance analysis (BIA) method 
using a body composition analyzer (OMRON, BF-511, Healthcare Co; Kyoto, Japan). 
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Laboratory Assessment 
Fasting blood samples (10ml) from all subjects were obtained after a 12-h overnight fast, at the 
beginning and end of the 8 weeks. The samples were centrifuged at 3000 rpm for 10 min to prepare 
serum and then stored at -80°C until analysis. Serum total antioxidant capacity (TAC) and oxidized 
LDL-cholesterol (OX-LDL) were determined by enzyme-linked immunosorbent assay using 
ELISA kits (Zellbio Gmbh, Ulm, Germany).  
Statistical Analyses   
All statistical analyses were conducted with SPSS software, version 22 (SPSS Inc., Chicago, IL, 
USA). Normal distribution of all variables was assessed using Kolmogorov-Smirnov test. All data 
were presented as mean ± SD. Chi-square test was applied to compare qualitative variables 
between the trial groups. Paired-samples t-tests were used to compare differences pre and post 
intervention within each group. The means of variables between groups were compared using both 
independent-samples t-tests and ANCOVA in the adjusted models. A p-value <0.5 was considered 
significant. 
 
Results 
Among the 78 dyslipidemic patients who participated in the study, 3 patients in the intervention 
group  and 5 patients in the control group, respectively, withdrew from the study, leaving 70 
participants included in the final analysis (Figure 1). Patients withdrew due to personal reasons 
and/or travel commitments. Baseline characteristics of the participants in study are shown in Table 
1. At baseline, Age, BMI, Weight, Waist circumference, OX-LDL, and TAC were not significantly 
different between groups. Changes in Oxidized LDL, and TAC after GCBE supplementation are 
indicated in Table 2. Compared with the placebo, GCBE intake led to a significant decline in OX-
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LDL (ng/ml) (P-valuea= ˂0.001) and a significant rise in TAC (μmol/l) concentration (P-valuea= 
0.029). In the intervention group GCBE supplementation resulted in a significant reduction in 
Oxidized LDL of -16.08±33.30 (ng/ml) compared to baseline. In addition, within-group 
comparisons also showed that the mean concentration of TAC significantly increased post-trial in 
the intervention group (mean difference: 130.55±134.75 (μmol/l), p˂0.001) and control group 
(mean difference: 58.824±83.40 (μmol/l), p˂0.001).  
Moreover, in the intervention group, weight (kg) (from 92.46 ± 15.2 to 91.82 ± 15.1, p=0.009), 
BMI (kg/m) (from 26.40 ± 4.3 to 26.21 ± 4.3, p=0.009), and mean visceral fat (%)  (from 13.3 ± 
4.4 to 12.53 ± 4.2 , p=0.018) reduced significantly. However, there were no significant changes in 
anthropometric indices in the placebo groups (the data are not shown in the table). 
 
Discussion 
Results of the present study indicated that supplementation with GCBE among participants with 
dyslipidemia for 8 weeks had favorable results on Oxidized LDL, and TAC.   
In agreement with the present trial, there are several studies that reported a similarly favorable 
effect of GCBE on metabolic variables.  A meta-analysis on three trial studies revealed GCBE 
intake resulted in significant weight loss (−2.47 kg)[36]. In another study, Hanieh Roshan et al. 
reported 400 mg GCBE supplementation for 8 weeks resulted in significantly reduced systolic 
blood pressure (SBP), fasting blood glucose (FBS), and homoeostatic model of assessment of 
insulin resistance, waist circumference, and appetite score in comparison to placebo [37]. In 
addition, Revuelta-Iniesta et al. showed GCBE consumption reduced systolic blood pressure, BMI 
and abdominal fat [38], whilst Watanabe et al. demonstrated CGA in GCBE led to decreased blood 
pressure, body mass index, pulse rate, routine blood test, urinalysis, and hematochemistry [39]. 
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Concordant with our study, Yukawa et al. reported that Oxidized LDL, as well as malondialdehyde 
(MDA) and thiobarbituric acid reactive substances (TBARS) were reduced after one week coffee 
consumption [40].  In addition, another study showed that a 4-week coffee intervention led to 
increased TAC and antioxidant enzyme activities, while there was no significant OX-LDL change 
[41]. However, recent empirical studies have not observed a significant change in OX-LDL 
following intervention of 800 ml/day of instant and filtered coffee [26, 42].  Although it is evident 
that the composition of green coffee differs from black coffee (BC) due to the roasting process, 
different study designs, different dosages of coffee and polyphenol content, as well as duration of 
the study likely contribute to the varied results among studies related to OX-LDL.  
An exact mechanism through which green coffee intake might influence OX-LDL is unknown. 
Ochiai R et al. reported that green coffee intake decreased plasma total homocysteine 
concentration [39]; thus green coffee intake may conceivably influence OX-LDL by reducing 
homocysteine, because homocysteine increases oxidation by promoting the formation of reactive 
oxygen species[43]. Recent evidence has shown that CGA has prominent antioxidant, 
anticarcinogenic activities and hypolipidemic effects, and is one of the most abundant polyphenol 
compounds in coffee [44-46]. The favorable effect of the GCBE administration on Oxidized LDL, 
and TAC may plausibly be mediated by polyphenols; in fact, our study found an association 
between serum TAC and green coffee antioxidant capacity that is confirmed in other studies [47-
49]. Moreover, Fausta Natella et al. in a study on ten healthy, nonsmoking, moderate coffee 
drinkers reported phenolic compounds are likely to be responsible for the increase in plasma 
antioxidant capacity after coffee drinking [50]. In agreement with the present study, there are 
several human and animal-based studies that have reported polyphenol supplementation promoted 
antioxidant capacity [49, 51, 52]. In addition, the effect of GCBE supplementation on OX-LDL 
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and TAC may be mediated through weight loss, because studies have shown that weight loss 
leading to significant reduction in OX-LDL and increase in TAC [53, 54]. Interestingly, the control 
group of the present study also appeared to have an increase in TAC – although at a lower level 
than the intervention group, that this could only conceivably be attributed to the placebo effect; 
nevertheless, further work must be conducted to confirm the veracity of our results. 
The strength of current trial lies in the double-blind, randomized, placebo-controlled design. 
However, there are several restrictions that need to be considered in interpreting the results of this 
study.  Firstly, the trial was conducted on a small group of homogenous males at a single location 
and the limited age range that makes extrapolation to other populations difficult. Further studies 
would therefore benefit from incorporating larger sample sizes and different intervention 
populations. Moreover, we were unable to measure additional antioxidant variables in our study, 
and future investigations are required to examine the effect of GCBE consumption on antioxidant 
enzymes and other biomarkers of oxidative stress. 
Conclusion 
The current trial showed that the intake of 800 mg per day of GCBE may have favorable effects 
on TAC and OX-LDL in patients with dyslipidemia. However, further studies are necessitated to 
confirm the veracity of these results. 
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Figure 1. Flow diagram of participant recruitment. 
Table 1. General characteristics of patients with dyslipidemia at the baseline. 
 
Variables Entire Cohort 
(n=70) 
intervention (n = 
36) 
control (n = 34) P_value 
Age(years) 39.18±6.09 39.85±6.46 38.49±5.69 0.340 
BMI(kg/m2) 26.13±3.65 26.31±4.19 25.95±3.04 0.666 
Weight(kg) 91.50±13.37 92.16±14.83 90.83±11.85 0.669 
Waist 
circumference)cm) 
104.92±9.30 104.39±10.41 105.45±8.10 0.623 
Oxidized 
LDL(ng/ml) 
64.56±74.52 63.82±69.89 65.35±80.18 0.933 
TAC (μmol/l) 383.14±91.75 368.06±104.49 399.12±74.23 0.158 
*Values are reported as mean ± standard deviation. 
BMI, Body Mass Index; p_value ≤0/05 was assigned as statistically significant. 
 
Table 2. The effect of green coffee extract supplementation on serum oxidized LDL cholesterol 
and total antioxidant capacity in patients with dyslipidemia. 
 
 intervention (n = 36) control (n = 34) p-
valuea  mean ± SD Mean Change mean ± SD Mean 
Change 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Oxidized 
LDL(ng/ml) 
     
Baseline 63.82±69.89 -16.08±33.30 65.35±80.18 15.10±53.34 ˂0.001 
End of trial 47.74±39.80  66.86±42.38   
P-valueb 0.006  0.870   
TAC (μmol/l)      
Baseline 368.06±104.49 130.55±134.75 399.12±74.23 58.824±83.40 0.029 
End of trial 498.61±110.87  457.94±51.155   
p-valueb ˂0.001  ˂0.001   
aObtained from ANCOVA (analysis of co-variance), adjusted for baseline values. bObtained 
from paired T test. 
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